12 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.
Therachem Research Medilab (India)
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Kyoto Prefectural University Of Medicine
Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
University Of Copenhagen
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University Of Oxford
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.
Nankai University
Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition.
Institute Of Biomolecular Chemistry (Icb)
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
The University Of Texas M.D. Anderson Cancer Center
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
